Fig. 1

The summary of this study. First step:The genomic DNA from 1000 Genomes Project and the genomic DNA from cancer cells were used to set up basic parameters of targeted NGS platform; The second step: The validation of targeted NGS platform was performed on a large number of clinical samples (n = 235); The third step: Performance of targeted NGS on variance detection from a large NSCLC cohort (n = 215). In brief, these results suggested high performance of targeted NGS on variance detection in clinical tumor specimens